ALK and non-small cell lung carcinoma: In the BRAVE study, a multicenter observational study of biomarker testing and first-line treatment for advanced NSCLC patients in Japan, the proportion of patients with a confirmed biomarker status, including for EGFR, ALK, ROS1, and PD-L1, for use in selecting the first-line treatment was 79.7% [19].